Improvement of newly diagnosed immune thrombocytopenia management in children by implementing revised practice...

Area of Science:

• Pediatric Hematology
• Clinical Practice Guidelines
• Evidence-Based Medicine

Background:

• Newly diagnosed immune thrombocytopenia (ITP) in children is usually transient, with severe bleeding rare despite low platelet counts.
• Observation without treatment is standard for children without significant bleeding, yet guidelines prioritizing bleeding scores over platelet counts are not widely adopted.

Purpose of the Study:

• To evaluate the safety and impact of implementing guidelines that use bleeding scores to guide ITP treatment decisions in a pediatric emergency department.
• To compare treatment and hospitalization rates, as well as complication and persistent ITP rates, before and after guideline implementation.

Main Methods:

• A retrospective study compared patient management in the pre-guideline (PRE) and post-guideline (POST) periods (January 2019-December 2020 vs. January 2022-December 2023).
• The new guideline recommended treatment for Buchanan score ≥3, irrespective of platelet count, differing from the previous platelet count <10 × 10⁹/L threshold.

Main Results:

• 84 children (34 PRE, 50 POST) were included, with comparable characteristics.
• The guideline was followed in 88% of POST cases, leading to increased observation without treatment (24% PRE vs. 58% POST) and decreased hospitalizations (62% PRE vs. 22% POST).
• Higher observation rates in patients with low bleeding scores drove these changes; no intracranial bleeding, death, or increased persistent ITP was observed.

Conclusions:

• Transitioning to bleeding score-based guidelines for pediatric ITP is safe and effective.
• This shift significantly reduced treatment and hospitalization rates in the emergency department setting.
• The findings support wider adoption of bleeding score-based guidelines for managing pediatric ITP.